180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced collection of all patient data for its phase 2b Dupuytren’s disease trial, which was sponsored by the University of Oxford. The double-blind placebo-controlled trial involved 181 patients who were randomized across three sites, two in the United Kingdom and one in the Netherlands. While follow-up on the trial has been delayed by the COVID-19 pandemic, the company is now analyzing the information and has plans to announce top-line data in an upcoming article in a peer-reviewed journal. The company also announced that it has received notification from the Listing Qualifications Department of the Nasdaq Stock Market that it is not in compliance with a Nasdaq Listing Rule requiring filing an annual report for fiscal year 2020. The notification letter has no immediate impact on the listing or trading of ATNF stock on the Nasdaq market. The company noted that it is reviewing the SEC statement; company auditors are also in the process auditing ATNF financial statements to complete the annual report as soon as practical. Regarding the phase 2b disease trial data, 180 Life Sciences CEO stated the following: “Despite the challenges posed by the COVID-19 pandemic and shut down of clinical sites across Europe due to government restrictions, we are fortunate to have had our investigators with the help of additional support from the Wellcome Trust, complete the collection of data. The data is being reviewed and validated, which is not an easy task under current conditions. The analysis will be according to the previously agreed Statistical Analysis Plan. We remain on track to announce a top-line data read out from this trial in Q4 2021.”
To view the full press releases , visit https://ibn.fm/p0uMd and https://ibn.fm/eRt6V
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. 180 Life Sciences’s primary platform is a novel program to treat fibrosis using anti-TNF (“TNF”) (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials. For more information about the company, visit www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.